Relmada Share Price

Relmada Share Price

NASDAQ: RLMD | Micro Cap | Healthcare
$2.92
-$0.08 (-2.82%) Last updated on 19 Nov, 2026 | 01:27 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

Relmada Stock Performance

Open
$3.00
Prev. Close
$3.01
Circuit Range
N/A
Day Range
$2.87 - $3.08
Year Range
$2.87 - $7.99
Volume
88,107
Average Traded
$2.94

Relmada Share Price Today

As of 19 November 2026, Relmada Therapeutics, Inc.'s share price is $2.92. The stock opened at $3.00, compared to its previous close of $3.01. During today's trading session, Relmada Therapeutics, Inc.'s share price traded between $2.87 and $3.08, with an average price of $2.98. Over the past 52 weeks, the stock has recorded a high of $7.99 and a low of $2.87. In terms of performance, Relmada Therapeutics, Inc.'s share price has declined by 59.49% over the last six months and is down 35.29% on a year-on-year basis.

Relmada Share Price Chart

Line chart of the Relmada price trend over the selected period. The price fell overall, ranging from 2.90 to 3.09, ending at 2.92.
$2.87$3.08
L
Show Current Price
H

Relmada Stock Fundamentals & Key Indicators

Market Cap
$115.48M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.62
Revenue (TTM)
$0.00
Return On Equity (TTM)
-33.91%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
30.25%

Relmada Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$19.87-$19.05-$12.91-$13.86
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A4.13%32.23%-7.36%

Relmada Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$0.00$0.00
Net Profit-$157.04-$98.79-$79.98-$57.39
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A37.09%19.04%28.24%

Relmada Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets0.020.020.040.03
Current Assets93.9845.897.51152.87
Total Assets94.045.8297.55152.91
Non Current Liabilities1.060.00.00.0
Current Liabilities6.4310.2912.1912.47
Total Liabilities7.4910.312.1912.47
Shareholders' Equity86.5135.5285.36140.44

Relmada Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-45.79-51.76-51.66-103.8
Investing-48.1451.5650.4519.73
Financing93.56-0.04-0.145.02

Corporate Actions

Split
Ex-date: 30 Sep 2019

About Relmada

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Relmada Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$3.60
$2.93
-18.04%
Oct 2026
$3.74
$3.58
-5.05%
Sep 2026
$4.34
$3.77
-16.70%
Aug 2026
$5.09
$4.52
-14.88%
Jul 2026
$6.83
$5.31
-23.38%
Jun 2026
$7.03
$6.93
-4.02%
May 2026
$7.61
$7.22
-4.18%
Apr 2026
$7.03
$7.54
+8.57%
Mar 2026
$4.71
$6.94
+53.20%
Feb 2026
$3.68
$4.53
+27.61%
Jan 2026
$4.75
$3.55
-26.42%
Dec 2025
$4.44
$4.83
+6.75%

Relmada Share Price FAQs